SYT-510

DRUG2 trials

Sponsors

Synendos Therapeutics AG

Conditions

Generalized Anxiety DisorderHealthy

Phase 1

A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants

CompletedNCT06670950

Synendos Therapeutics AGHealthy

Start: 2024-11-04End: 2025-05-23Updated: 2026-06-10

Phase 2

A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder

RecruitingNCT07478744

Synendos Therapeutics AGGeneralized Anxiety Disorder

Start: 2026-04-22End: 2027-01-01Target: 24Updated: 2026-06-18